Taltz (ixekizumab) Letter of Medical Necessity
Taltz (ixekizumab) prior authorization commonly requires step therapy through a TNF inhibitor and documented severity scores. When secukinumab is preferred on formulary, the LMN must justify ixekizumab selection.
FDA-Approved Indications
- ● plaque psoriasis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● non-radiographic axial spondyloarthritis
Why Taltz Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. TNF inhibitor not tried first (step therapy)
- 2. Preferred IL-17 inhibitor (secukinumab) on formulary
- 3. Severity scoring not documented
- 4. IBD history flagged as contraindication
What to Include in a Taltz Letter of Medical Necessity
Document diagnosis with severity metrics (PASI/BSA for psoriasis, BASDAI for axSpA, ACR for PsA), prior TNF and other biologic trial outcomes, confirmation of no active IBD, and the clinical rationale for ixekizumab over preferred IL-17 or other biologic alternatives.
Key clinical evidence to cite:
- ✓ UNCOVER 1-3 (psoriasis)
- ✓ SPIRIT-P1 and P2 (PsA)
- ✓ COAST-V and COAST-W (axSpA)
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
- 📖 ASAS 2022 axSpA Update
Taltz Prior Authorization Criteria
Standard criteria across major US payers for Taltz. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → TNF inhibitor not tried first (step therapy)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Taltz
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Taltz Prior Authorization FAQ
Why was my Taltz prior authorization denied?
The most common denial reasons for Taltz are: TNF inhibitor not tried first (step therapy); Preferred IL-17 inhibitor (secukinumab) on formulary; Severity scoring not documented; IBD history flagged as contraindication.
What should a Taltz Letter of Medical Necessity include?
Document diagnosis with severity metrics (PASI/BSA for psoriasis, BASDAI for axSpA, ACR for PsA), prior TNF and other biologic trial outcomes, confirmation of no active IBD, and the clinical rationale for ixekizumab over preferred IL-17 or other biologic alternatives.
Which payers cover Taltz?
Taltz is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, though formulary tier and prior authorization criteria vary.